Nevertheless, the tissue-specific improvement of cortisol metabolism via 11beta-HSD1 inhibition is still of high interest in treatment of T2DM and parameters the metabolic syndrome, mainly obesity and hyperlipidemia. The gene discussed is HSD11B1; the disease is obesity due to melanocortin 4 receptor deficiency.